345 related articles for article (PubMed ID: 18504438)
21. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.
Powers JT; Tsanov KM; Pearson DS; Roels F; Spina CS; Ebright R; Seligson M; de Soysa Y; Cahan P; Theißen J; Tu HC; Han A; Kurek KC; LaPier GS; Osborne JK; Ross SJ; Cesana M; Collins JJ; Berthold F; Daley GQ
Nature; 2016 Jul; 535(7611):246-51. PubMed ID: 27383785
[TBL] [Abstract][Full Text] [Related]
22. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics.
Stallings RL
Curr Pharm Des; 2009; 15(4):456-62. PubMed ID: 19199973
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
25. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
26. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
27. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
Chen Y; Stallings RL
Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
[TBL] [Abstract][Full Text] [Related]
28. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death.
Munirajan AK; Ando K; Mukai A; Takahashi M; Suenaga Y; Ohira M; Koda T; Hirota T; Ozaki T; Nakagawara A
J Biol Chem; 2008 Sep; 283(36):24426-34. PubMed ID: 18614535
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells.
Jurcevic S; Keane S; Borgmästars E; Lubovac-Pilav Z; Ejeskär K
Sci Rep; 2022 Nov; 12(1):19729. PubMed ID: 36396668
[TBL] [Abstract][Full Text] [Related]
30. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
31. No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
Hogarty MD; Winter CL; Liu X; Guo C; White PS; Look AT; Brodeur GM; Maris JM
Cancer Res; 2002 Nov; 62(22):6481-4. PubMed ID: 12438240
[TBL] [Abstract][Full Text] [Related]
32. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
33. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
34. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
35. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
38. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
39. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
